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Abstract (words 248)  
 
Objectives 
Two thirds of individuals identified as ultra-high risk for psychosis do not develop psychotic 
disorder over the medium-term. This paper examines their outcome, including persistent 
attenuated psychotic symptoms, and incident and persistent non-psychotic disorders.  
 
Method 
Participants were help-seeking individuals identified as being at ultra-high risk for psychosis 
between two and 14 years previously (median=5.7). The current sample consists of 226 
participants (125 females; 101 males) who completed follow-up assessment and had not 
developed psychosis. Mean age at follow-up was 25.5 years (SD=4.8). 
 
Results  
Significant psychopathology was found; 28% reported attenuated psychotic symptoms at 
follow-up; 68% of participants experienced non-psychotic disorder over the follow-up period; 
48% experienced mood disorder, 34% anxiety disorder and 29% a substance use disorder. 
For a majority, non-psychotic disorder was present at baseline (90%), and was persistent for 
57% of them. Over the follow-up period, 26% of the cohort remitted from a disorder, but 
37% developed a new disorder. Only 7% did not experience any disorder over follow up. 
 
The incidence of non-psychotic disorder was associated with higher negative symptoms at 
baseline. Females experienced higher rates of persistent/recurrent disorder. Meeting the brief 
limited intermittent psychotic symptoms group at intake was associated with lower risk for 
persistent/recurrent disorder.  
 
Conclusions 
Non-transitioned ultra-high risk cases are at significant risk for ongoing attenuated psychotic 
symptoms, and persistent/recurrent and incident disorders. The ultra-high risk phenotype, 
while relatively specific to incident psychosis, also captures patients with a range of emerging 
or chronic psychopathology. Findings have implications for ongoing clinical care.  
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Introduction 
The period of illness preceding the onset of psychotic disorder has received growing 
attention since the introduction of criteria for identifying youth at ultra-high risk for 
psychosis (1). These combine state and trait risk factors to identify young people potentially 
in the prodrome of psychotic illness. A recent meta-analysis (2) indicated that the average rate 
of transition to psychotic disorder across samples was 36% after three years. Although this 
reflects a much higher rate of psychosis than in the general population or other clinical 
samples, two thirds of those identified as at-risk do not develop psychotic disorder in the 
medium-term. 
One possible explanation is that the majority of individuals referred to at-risk services 
present with transient psychotic experiences and, although they fulfil at-risk criteria, this is 
not always indicative of impending psychotic illness (3). Subclinical psychotic experiences 
often occur in the general population, but persist in only a small proportion of those who 
report them (4), and an even smaller proportion develop a psychotic disorder (5). Rather than 
indicating psychotic disorder, these experiences may be related to other psychopathology, 
such as depression and anxiety (6, 7), which are common in at-risk samples (8-12).    
Given the common occurrence of non-psychotic disorders in young people meeting 
at-risk criteria (8-12) and the declining rate of transition to psychotic disorder in recent 
cohorts (13, 14), it is important to examine the outcomes of those individuals who do not 
develop psychosis. Results from small samples show high rates of mood disorder at six (15) 
and 12-month follow-up (16-18). Anxiety disorders are also common (16, 17). In a large at-
risk sample, Addington and colleagues (19) showed that, in the group who did not develop 
psychosis 29% had mood disorder and 38% had anxiety disorder after one year. These rates 
dropped to 15% and 32% respectively by two year follow-up (19). Substance use disorders 
were also prevalent, but also reduced after two years. These high rates suggest that young 
people meeting at-risk criteria who do not develop psychosis continue to experience 
significant mental health problems. 
It is also possible that non-transitioned cases continue to experience attenuated 
psychotic symptoms and may still meet at-risk criteria. Rates of attenuated psychotic 
symptoms at one year follow-up vary from 23% to 42% (16, 18, 19). At two years, attenuated 
symptoms are evident in 35% (20) and 40% (19) of at-risk samples, and 25% (21) and 50% 
(22) at 3 years. Continued attenuated symptoms could represent an extended prodrome with 
transition to psychosis yet to occur. Alternatively, young people with attenuated symptoms 
may not be prodromal, but their ongoing  symptoms may be distressing and disabling in their 
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own right and may be comorbid with threshold or subthreshold mood or anxiety disorder. 
Although there are now substantial data on persistent attenuated psychotic symptoms, 
definitions and rates are inconsistent, making it difficult to ascertain true remission rates.  
There is also a lack of data on the course of psychopathology for at-risk young people 
who do not develop psychosis. In the current study we investigated the presence of attenuated 
psychotic symptoms, the prevalence and course of non-psychotic DSM-IV diagnoses, and 
predictors of non-psychotic outcomes in those who did not transition to psychotic disorder 
from a cohort identified as ultra-high risk between two and 14 years previously [the PACE 
400 sample (14)]. Based on the previous studies with short- to medium-term follow-up 
periods (15-19), we expected high rates of non-psychotic psychopathology in this group.  
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Method 
Participants and procedure 
PACE is a specialist clinic for young people at ultra-high risk for psychosis, in 
Melbourne, Australia. The current data was part of a longitudinal study aiming to reassess all 
research participants at PACE between 1993 and 2006 (N=416). Follow-up interviews were 
completed by 311 participants (74.8%), 85 of whom had developed psychotic disorder [see 
(14)]. The current sample consists of 226 participants (125 females; 101 males) who 
completed follow-up assessment but had not transitioned to psychosis. Figure 1 shows the 
composition of the current sample.  
At baseline, participants were aged 15 to 30 years and met ultra-high risk criteria.  
These are: 1) attenuated psychotic symptoms, 2) brief limited intermittent psychotic 
symptoms, and/or 3) trait vulnerability for psychotic illness (schizotypal personality disorder 
or history of psychosis in a first-degree relative) and deterioration in functioning or chronic 
low functioning [see (14) for full description of determination of ultra-high risk status of this 
cohort]. Exclusion criteria for entry to PACE are a previous psychotic episode, organic cause 
for presentation or past anti-psychotic exposure equivalent to a haloperidol dose of >15 mg.  
A previously developed tracking system (23) was used to relocate participants. If 
participants did not consent to face-to-face assessment, they were asked for a telephone 
interview or written assessment. This study was approved by the local Research and Ethics 
Committee. All participants provided written informed consent.  
 
Measures 
Current assessment (follow-up): Axis I diagnoses at two to 14 year follow-up were assessed 
using the Structured Clinical Interview for DSM-IV [SCID-I; (24)]. Face-to-face interview 
was completed for 194 (85.5%), a telephone interview for 29 (12.8%) and in writing for three 
participants (1.3%). The Comprehensive Assessment of At-Risk Mental States [CAARMS; 
(25)] was used to assesses the presence of attenuated psychotic symptoms.  
 
Previous assessments performed at initial presentation to PACE (baseline): Baseline 
psychopathology was measured using the Brief Psychiatric Rating Scale [BPRS; (26)],  Scale 
of Assessment for Negative Symptoms [SANS; (27)], and CAARMS (25). The BPRS 
psychotic subscale included items: unusual thought content, hallucinations, suspiciousness 
and conceptual disorganisation. BPRS affective subscale included items: anxiety, depression, 
guilt, somatic concerns and tension. CAARMS positive subscales were disorders of thought 
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content, perceptual abnormalities and conceptual disorganisation. General functioning was 
assessed with the Global Assessment of Functioning (GAF). Diagnoses were assessed using 
the SCID-I. 
Current IQ was measured using the Wechsler Adult Intelligence Scale-Revised 
[WAIS-R; (28)] or the Wechsler Abbreviate Scale of Intelligence [WASI; (29)]. Eight of the 
younger participants were assessed using the Wechsler Intelligence Scale for Children 
[WISC-III; (30)] as an alternative to the WAIS-R at baseline. IQ was estimated using 1) 
Ward’s (31) 7-subtest estimate of verbal, performance and full-scale IQ (n=52); 2) 
Kaufman’s 4-subtest (32) estimate of full-scale IQ (n=9); or 3) WASI estimate of verbal, 
performance and full-scale IQ (n=123).  
 
Statistical analyses 
Data were examined for the frequency of current attenuated psychotic symptoms, 
non-psychotic DSM-IV disorders during the follow-up period (current or since baseline) and 
the course of disorders. Three disorder groups were examined: mood, anxiety and substance 
use disorders, as well as the frequency and course of any disorder. Somatoform and eating 
disorders occurred rarely and were not included.  
The course of disorders was examined for participants who had diagnostic assessment 
at baseline and follow-up (n=203 for mood/anxiety; n=192 for substance use). Participants 
were classed as ‘never’ if the disorder was not present at baseline or during follow-up; 
‘persistent/recurrent’ if disorder was present at baseline and during follow-up; ‘remission’ if 
disorder was present at baseline but absent during follow-up; ‘incident’ if disorder was absent 
at baseline but present during follow-up (see Figure 2).  
To investigate candidate predictors of the course of disorders, participants with 
incident disorder were compared to participants who never had the disorder. Participants with 
persistent/recurrent disorder were compared to those with remitted disorder. Candidate 
predictors were intake group, GAF, BPRS psychotic score, BPRS affective score, SANS 
total, CAARMS disorders of thought content, CAARMS perceptual abnormalities, CAARMS 
conceptual disorganization, verbal IQ, performance IQ and full-scale IQ. For primary 
analyses, predictors with a univariate association at p-value <0.1 were entered together into 
binary logistic regression to identify the strongest predictors. Age at baseline, gender and 
length of the follow-up period were always included as predictors in binary logistic 
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regressions. Analysis was conducted for mood, anxiety and substance use disorders 
separately, and then for any disorder.  
Given the large variability in follow-up period, the cohort was divided into three 
subsamples based on when they were identified as at-risk: long- (1993-2000, N=82), 
medium- (2001-2003, N=77) and short-term follow-up periods (2004-2006, N=67). 
Frequencies are presented for the entire cohort and each subsample. Given the volume of 
data, some analyses are presented in online supplementary data only, as is exploratory 
analyses of neurocognitive predictors of the course of disorders.  
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Results 
 
Sample characteristics 
More females completed follow-up than males (55.3% female; χ2=5.12, p=0.02). 
There were no other significant differences between participants who were followed-up and 
those that were not. The mean age of participants at baseline was 18.6 years (SD=3.3) and 
25.5 years (SD=4.8) at follow-up. Follow-up was conducted between 2.4 and 14.1 years after 
baseline (M=6.9; SD=3.1; median=5.72). Eighty- two (36.3%) participants received trial 
treatment while attending PACE [cognitive-behaviour therapy (n=25); cognitive-behaviour 
therapy and low-dose antipsychotics (n=38); low-dose lithium (n=19), all ≤12 months]. There 
were no significant differences between participants who received trial treatment and those 
who did not on rates of disorders during follow-up. Further characteristics for each subsample 
are presented in Supplementary Table 1. 
 
Frequency and comorbidity of non-psychotic disorders at follow-up   
Diagnostic outcomes at follow-up are presented in Table 1. Of the entire cohort, 
68.1% met criteria for at least one disorder during the follow-up period. Mood disorder was 
present during follow-up for 48.7%, anxiety disorder for 34.5% and substance use disorder 
for 29.2%. Proportions were not notably different between subsamples. 
For the entire cohort, both mood and anxiety disorders were present in 24.3%, mood 
and substance use disorders in 17.7%, anxiety and substance use disorders in 13.7% and all 
three disorders in 10.2%. Patterns of comorbidity were similar in the 1993-2000 and 2003-
2006 subsamples, but lower in the 2001-2003 group (see Table 1).  
 
Attenuated psychotic symptoms  
The proportion of participants reporting attenuated psychotic symptoms at follow-up 
that were at or above the threshold for ultra-high risk was 28.3% for the entire cohort, 24.4% 
for the 1993-2000 subsample, 23.4% for the 2001-2003 subsample, and 41.9% for the 2004-
2006 subsample (data missing for 30 of the participants with telephone/written assessment at 
follow-up). 
The co-occurrence of attenuated symptoms and non-psychotic disorders at follow-up 
is presented in Table 2. For the entire cohort, the presence of attenuated psychotic symptoms 
was significantly associated with a mood disorder (χ2=7.81, p=0.005) and with any non-
psychotic disorder over the follow-up period (χ2=5.91, p=0.02), but not with anxiety and 
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substance use disorders. Results were similar for the 2004-2006 subsample (mood disorders, 
χ2=9.14, p=0.003; any disorder, χ2=8.19, p=0.004).  
 
Course of non-psychotic disorders 
The frequency of baseline disorder, remission, incidence, persistence/recurrence and 
absence of non-psychotic disorders is shown in Table 3. Below we report results for the entire 
cohort. Of the participants who had a mood disorder at baseline (64.2%), 53.8% had 
persistent/recurrent disorder. In those without mood disorder at baseline, 32.8% developed 
one. Of those with anxiety disorder at baseline (35.8%), 40.7% experienced 
persistent/recurrent anxiety. Of those without anxiety disorder at baseline, 29.5% developed 
one. Substance use disorders were present at baseline for 21.9% individuals (of 192 with 
available baseline substance use diagnoses). Of them, over half (52.4%) showed persistent/ 
recurrent substance use disorder over follow-up. Of those without substance use disorder at 
baseline, 22.3% developed a substance use disorder.  
In terms of any disorder, 90.1% of the cohort had any non-psychotic disorder at 
baseline. Over the follow-up period, 26.0% of the entire cohort remitted from a disorder, but 
37.5% developed a new disorder. 57.2% of the cohort had a persistent/recurrent non-
psychotic disorder. Only 7.3% never experienced any disorder. 
For the most part, the course of disorders were not notably different between 
subsamples, with the exception of the 2004-2006 subsample presenting with lower rates of 
substance use disorders at baseline. However, the rate of incident substance use disorder in 
this subsample was comparable to the other groups. 
 
Predictors of the incident disorder and remission  
 Baseline symptomatology, GAF, IQ and age were poor predictors of the course of 
disorder. Gender emerged as a significant predictor of specific disorders, although the overall 
models were not statistically significant. Being female was associated with 
persistent/recurrent mood disorder, compared to remitted mood disorder (odds ratio=2.07, 
95% CI for odds ratio=1.02-4.23, p=0.05), and with incident anxiety disorder compared to 
never having an anxiety disorder (odds ratio=2.66, 95% CI for odds ratio=1.11-6.39, p=0.03).  
The incidence of any disorder was associated with higher baseline scores on the 
SANS (odds ratio=1.14, 95% CI for odds ratio=1.01-1.29, p=0.03) compared to never having 
a disorder. The persistence/recurrence of any disorder, as opposed to remission from any 
disorder, was associated with being female (odds ratio=2.40, 95% CI for odds ratio=1.12-
11 
 
5.15, p=0.02). Meeting the criteria for brief limited intermittent psychotic symptoms at intake 
to PACE was associated with a decreased chance of persistent/recurrent disorder (odds 
ratio=0.19, 95% CI for odds ratio=0.05-0.72, p=0.01). Despite its variability, the length of 
follow-up did not predict the course of disorder in the entire cohort. 
Predictors of the course of disorders for each subsample and exploratory analyses of 
neurocognitive performance are presented in online supplementary data.  
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Discussion 
In this study, we examined the clinical outcome for individuals who did not transition to 
psychotic illness in a cohort identified as ultra-high risk for psychosis between two and 14 
years earlier. The frequency and course of mood, anxiety and substance use disorders were 
examined. Approximately a quarter of cases experienced attenuated psychotic symptoms at 
follow-up assessment. Non-psychotic disorders were often present at baseline, and tended to 
persist over the follow-up period. Incident non-psychotic disorder was also common, 
occurring in over one third of the sample. Baseline and demographic variables were not 
strong predictors of the course of non-psychotic disorders. 
 
Persistent attenuated psychotic symptoms 
Twenty-eight per cent of the current sample reported attenuated psychotic symptoms at 
follow-up assessment. If considered together with the cases in the cohort that developed 
psychotic disorder (14), half of the young people who met ultra-high risk criteria at PACE 
showed continued or recurrent positive psychotic symptoms (threshold or subthreshold).  
The presence of attenuated psychotic symptoms may reflect that some individuals are 
still at risk for psychosis. This is possible since transitions occurred up to ten years after 
identification of risk in this sample (14), [although most transitions occurred within the first 
two years]. Alternatively, it may indicate attenuated symptoms occurring in the context of 
non-psychotic disorders, which may resolve with resolution of that disorder (3, 6, 7). This 
would be consistent with the idea of “incidental” psychotic symptoms (33). The fact that 
participants with the shortest follow-up period showed the highest rates of attenuated 
symptoms, and that their attenuated symptoms were associated with non-psychotic disorders, 
could support either of these possibilities.  
 
Non-psychotic disorders  
Mood disorders were the most common diagnosis during follow-up, specifically major 
depressive disorder. This was followed by high rates of anxiety disorders, cannabis 
dependence and alcohol abuse. These rates are higher than would be expected in the general 
population. A detailed comparison of our cohort with Australian general population data (34) 
is presented in online Supplementary Table 3. Briefly, the rates of non-psychotic disorders in 
this cohort were higher than the 12-month prevalence of these disorders for a similar age 
group in the general population, as well as higher than lifetime prevalence of adults of all 
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ages. Most notably, the prevalence of mood disorder over the follow-up period (two to 14 
years) in our cohort was increased by a factor of five compared to 12-month prevalence and a 
factor of three compared to lifetime prevalence in the general population.   
This would be expected of a selected help-seeking sample. Indeed, many non-
psychotic disorders were already present at baseline. The important point is that disorders 
persisted for approximately half of these young people who did not develop psychosis. In 
addition, for those without a non-psychotic disorder at baseline, the incidence of new 
disorders was common. In fact, over a third of the sample developed an incident disorder 
over the follow-up period. Thus the ultra-high risk criteria might also represent a useful 
system for identifying young people at risk for chronic and emerging non-psychotic disorder, 
especially since they are already linked with youth mental health services. This highlights the 
need for further investigation to develop a better understanding of the risk factors associated 
with non-psychotic disorder in this population. 
We explored positive and negative psychotic symptoms, affective symptoms, 
functioning, IQ, gender and age as predictors of incident or persistent/recurrent non-psychotic 
disorder.  Being female was associated with a higher risk of disorder than being male, 
consistent with general population data (34). However, no other baseline variables were 
associated with the course of a specific disorder, which may be due to a lack of statistical 
power. Interestingly, higher SANS scores at baseline and not meeting brief limited 
intermittent psychotic symptoms criteria were associated with the incidence and 
persistence/recurrence of any disorder, respectively. This could demonstrate the specificity of 
brief limited intermittent psychotic symptoms to psychotic disorder and, on the other hand, 
the non-specificity of symptoms measured on the SANS. It may be that some depressive 
symptoms were interpreted as negative symptoms and rated on the SANS. Alternatively, 
those with high negative symptoms and depressive disorder may continue to be in the 
prodrome of a psychotic disorder, as depression and negative symptoms are known to occur 
during this phase in schizophrenia (35, 36).  
Although highly variable, the length of the follow-up period was not strongly 
associated with the course of disorders. Notably, in the subsample with the shortest follow-up 
period (2004-2006), persistence/recurrence of any disorder was associated with a shorter 
follow-up period. This is consistent with the decrease in the rate of non-psychotic disorders 
that was noted by Addington and colleagues (19). Together with the finding of considerably 
higher attenuated psychotic symptoms in the 2004-2006 subsample, our data suggest that the 
time for which participants are monitored may be important over the short-term (first two to 
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four years), but becomes less important over the longer-term. This has implications for many 
studies, which typically track at-risk participants for one to three years.  
The lack of strong predictors of non-psychotic disorder is distinctly different from the 
prediction of psychotic illness in at-risk samples, where a number of baseline symptoms are 
consistently shown to be associated with the onset of psychosis. However, this does not imply 
that the course of non-psychotic illness cannot be predicted. Rather, it suggests that clinical 
variables that predict non-psychotic disorder are different from those that predict the onset of 
psychotic illness, highlighting the need to design studies with a focus on multiple outcomes at 
inception (37).  
The strength of this study is the large sample size recruited from a single site, the long 
follow-up period and high follow-up rates. The greatest limitation is the variable length of the 
follow-up period. Although we have presented data for the entire cohort as well as for 
subsamples of short-, medium- and long-term follow-up, subsamples do differ in some 
respects and analyses are complicated by this. Moreover, the epochs used are arbitrary.  
It is important to acknowledge that we did not document treatment over the follow-up 
period, which is likely to influence the course of disorder. Another limitation is that follow-up 
diagnosis of 32 participants was made via telephone or written interview. Finally, females 
were over-represented at follow-up, which may bias towards higher levels of mood and 
anxiety disorder.  
The current findings demonstrate significant psychopathology in non-transitioned 
cases two to 14 years after identification of risk. Persistent or recurrent non-psychotic 
disorders were frequent even though these young people had previously been involved with 
youth mental health services, albeit in a time-limited manner. Clinically, the results suggest 
the need for at-risk clinics to include non-psychotic outcomes in their treatment and follow-
up plans to provide longer-term care.  
We have previously proposed a clinical staging model that posits that severe mental 
disorders such as schizophrenia, bipolar disorder and severe unipolar depression develop 
from initial non-specific symptoms, such as depressed mood, anxiety and distress (38). 
Acquisition of new symptoms, including psychotic symptoms and worsening of emotional 
dysregulation occurs in some people, who might then meet the at-risk for psychosis criteria. 
From this clinical picture, a number of trajectories and outcomes are possible, including the 
major mental disorders noted above, remission, or persistence of subthreshold syndromes. 
The ultra-high risk criteria were developed to detect incident psychotic disorders and have 
proved valid to that end. It is not surprising therefore that they identify high rates of 
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schizophrenia (39). Future studies need to investigate the risk factors for chronic and incident 
non-psychotic disorder by incorporating variables of interest to non-psychotic outcome in 
their designs, for example Axis II disorders, mood disturbance, cognitive biases or family 
history of non-psychotic disorders. This will increase the understanding of the factors 
associated with the course of disorders in this population, and how they can best be treated. 
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Text for Figures 
 
Figure 1. Composition of the PACE ultra-high risk cohort and current sample 
Note. The current sample (N=226) is indicated in bold. Of the 203 with diagnostic 
information at baseline and follow-up, 11 were missing substance use diagnoses at baseline. 
 
Figure 2. Definitions used for the course of non-psychotic disorders in this study  
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Table 1. Rates of Axis I diagnoses during the follow-up period 
 
 
 
Note: Bipolar disorder refers to non-psychotic cases only. 
*Other mood disorders refers to depressive disorder not otherwise specified, bipolar disorder 
not otherwise specified and substance-induced mood disorders. Other anxiety disorder refers 
to anxiety disorder not otherwise specified or substance-induced anxiety disorder. Other drug 
abuse and dependence refers to sedatives, opioids, paint sniffing or hallucinogens. 
 Entire cohort 
N=226 
1993-2000  
N=82 
2001-2003 
N=77 
2003-2006  
N=67 
 N % N % N % N % 
Any disorder 154 68.1 56 68.3 53 68.8 45 67.2 
         
Any mood disorder 110 48.7 41 50.0 34 44.2 35 52.2 
Major depressive disorder 92 40.7 35 42.7 29 37.7 28 41.8 
Dysthymic disorder 8 3.5 2 2.4 0 0.0 6 9.0 
Bipolar I disorder 6 2.7 2 2.4 3 3.9 1 1.5 
Bipolar II disorder 3 1.3   3 3.9 0 0.0 
Other mood disorders* 2 0.9 1 1.2 1 1.3 0 0.0 
         
Any anxiety disorder 78 34.5 30 36.6 23 29.9 25 37.3 
Panic disorder with agoraphobia 11 4.9 2 2.4 3 3.9 6 9.0 
Panic disorder without agoraphobia 16 7.1 6 7.3 4 5.2 6 9.0 
Agoraphobia without panic 6 2.7 3 3.7 3 3.9 0 0.0 
Social phobia 25 11.1 11 13.4 6 7.8 8 11.9 
Specific phobia 8 3.5 2 2.4 3 3.9 3 4.5 
Generalised anxiety disorder 14 6.2 6 7.3 2 2.6 6 9.0 
Obsessive compulsive disorder 7 3.1 3 3.7 2 2.6 2 3.0 
Post-traumatic stress disorder 10 4.4 6 7.3 2 2.6 2 3.0 
Other anxiety disorder* 6 2.7 2 2.4 2 2.6 2 3.0 
         
Any substance use disorder 66 29.2 27 32.9 21 27.3 18 26.9 
Alcohol abuse 23 10.5 10 12.2 8 10.4 5 7.5 
Alcohol dependence 20 8.8 10 12.2 5 6.5 5 7.5 
Cannabis abuse 7 3.1 2 2.4 3 3.9 2 3.0 
Cannabis dependence 33 14.6 16 19.5 9 11.7 8 11.9 
Amphetamine/stimulant abuse 15 6.6 6 7.3 5 6.5 4 6.0 
Amphetamine/stimulant 
dependence 
10 4.4 3 3.7 4 5.2 3 4.5 
Other drug abuse* 14 6.2 4 4.9 6 7.8 4 6.0 
Other drug dependence* 7 3.1 3 3.7 1 1.3 3 4.5 
         
Any somatic disorder ǂ 6 2.7 4 4.9 1 1.3 1 1.5 
Any eating disorder ǂ 11 4.9 2 2.4 3 3.9 6 9.0 
         
Mood + Anxiety 55 24.3 24 29.3 11 14.3 20 29.9 
Mood + Substance use 40 17.7 17 20.7 10 13.0 13 19.4 
Anxiety + Substance use 31 13.7 14 17.1 9 11.7 8 11.9 
All three disorders 23 10.2 12 14.6 4 5.2 7 10.4 
18 
 
ǂ Any somatoform disorder refers to body dysmorphic disorder, hypochondriasis, 
undifferentiated somatoform disorder, pain disorder or somatoform disorder not otherwise 
specified. Any eating disorder refers to anorexia nervosa, bulimia nervosa, binge eating 
disorder or eating disorder not otherwise specified. 
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Table 2. Co-occurrence of attenuated psychotic symptoms and non-psychotic disorders at follow-up assessment 
 Entire cohort 1993-2000 2001-2003 2004-2006 
 Attenuated 
psychotic 
symptoms 
(n=64) 
No 
attenuated 
psychotic 
symptoms 
(n=132) 
Attenuated 
psychotic 
symptoms 
(n=20) 
No 
attenuated 
psychotic 
symptoms 
(n=50) 
Attenuated 
psychotic 
symptoms 
(n=18) 
No 
attenuated 
psychotic 
symptoms 
(n=46) 
Attenuated 
psychotic 
symptoms 
(n=26) 
No 
attenuated 
psychotic 
symptoms 
(n=36) 
 N % N % N % N % N % N % N % N % 
Mood disorder 42 65.6 57 43.2 13 65.0 24 48.0 8 44.4 19 41.3 21 80.8 14 38.9 
Anxiety disorder 31 48.4 46 34.8 12 60.0 18 36.0 6 33.3 17 37.0 13 50.0 11 30.6 
Substance use disorder 27 42.2 39 29.5 8 40.0 19 38.0 9 50.0 12 26.1 10 38.5 8 22.2 
Any non-psychotic 
disorder 54 84.4 88 66.6 16 80.0 36 72.0 14 77.7 32 69.6 24 92.3 20 55.5 
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Table 3. Course of non-psychotic disorders 
 
 
 
 
 
Entire 
cohort  
(N=203)* 
1993-2000 
(N=61)* 
2001-2003 
(N=77) 
2004-2006  
(N=65) 
PRESENT AT BASELINE   N % N % N % 
Any disorder  173 90.1 47 94.0 73 94.8 53 81.5 
Any mood disorder  145 71.4 33 54.1 61 79.2 51 78.5 
Any anxiety disorder  81 39.9 21 34.4 34 44.2 26 40.0 
Any substance use disorder  42 21.9 17 34.0 21 27.3 4 6.1 
REMISSION     
Any disorder 50 26.0 12 24.0 22 28.6 16 24.6 
Any mood disorder 67 33.0 13 21.3 31 40.3 23 35.4 
Any anxiety disorder 48 23.6 13 21.3 22 28.6 13 20.0 
Any substance use disorder 20 10.4 7 14.0 12 15.6 1 1.5 
INCIDENT     
Any disorder 72 37.5 24 48.0 24 31.2 24 36.9 
Any mood disorder 19 9.3 9 14.8 4 5.2 6 9.2 
Any anxiety disorder 36 17.7 13 21.3 11 14.3 12 18.5 
Any substance use disorder 33 17.2 7 14.0 12 15.6 14 21.5 
PERSISTENCE/ RECURRENCE    
Any disorder 99 51.6 29 58.0 40 51.9 30 46.1 
Any mood disorder 78 38.4 20 32.8 30 39.0 28 43.1 
Any anxiety disorder 33 16.2 8 13.1 12 15.6 13 20.0 
Any substance use disorder 22 11.5 10 20.0 9 11.7 3 4.6 
NEVER      
Any disorder 14 7.3 5 10.0 3 3.9 6 9.2 
Any mood disorder 39 19.2 19 31.1 12 15.6 8 12.3 
Any anxiety disorder 86 42.3 27 44.3 32 41.6 27 41.5 
Any substance use disorder 117 60.9 26 52.0 44 57.1 47 72.3 
 
*11 participants in the 1993-2000 subsample had no available substance use disorder data at baseline. 
Hence, N for the entire cohort is 203 for mood and anxiety disorders, and 192 for substance use 
disorder or any disorder. N for 1993-2000 is 61 for mood and anxiety disorders, and 50 substance use 
disorder or any disorder. 
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Figure 1. Composition of the PACE ultra-high risk cohort and current sample 
Note. The current sample (N=226) is indicated in bold. Of the 203 with diagnostic 
information at baseline and follow-up, 11 were missing substance use diagnoses at baseline. 
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Figure 2. Definitions used for the course of non-psychotic disorders in this study  
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